Berotralstat Treatment in Children With Hereditary Angioedema
Trial details
- Registry ID
- NCT05453968
- Phase
- Phase 3
The FDA approved Berotralstat (BCX7353) on 3 Dec 2020.
Drug identity checked against registry records
Also recorded as BCX7353; Orladeyo®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Berotralstat Treatment in Children With Hereditary AngioedemaNCT05453968 | BioCryst Pharmaceuticals | Phase 3 | Active not recruiting | 2024-09-11Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2020-12-03Day | Berotralstat | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA214094", "applicant_as_listed_by_fda": "BIOCRYST", "brand_names": ["ORLADEYO"], "active_ingredients": ["BEROTRALSTAT DIHYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20201203", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |